International Clinical Trial: Comparison of Viral Suppression With 0.5 mg and 1.0 mg Daily Doses of Entecavir in Decompensated HBV Cirrhosis of Liver

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07816094) titled 'Comparison of Viral Suppression With 0.5 mg and 1.0 mg Daily Doses of Entecavir in Decompensated HBV Cirrhosis of Liver' on Sept. 7.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Bangladesh Medical University

Condition: Hepatitis B

Intervention: Drug: Entecavir

Recruitment Status: Recruiting

Phase: Phase 4

Date of First Enrollment: January 1, 2026

Target Sample Size: 48

Countries of Recruitment: Bangladesh

To know more, visit https://clinicaltrials.gov/study/NCT07816094...